CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings
Cannabis Bioscience International Holdings (CBIH) has significantly expanded its patent portfolio by filing six utility non-provisional applications for cannabinoid-based therapies. The patents cover treatments for pancreatic cancer, breast cancer, herpes zoster, menopause, knee osteoarthritis, and COVID-19/Influenza. Under the guidance of newly appointed patent attorney Mauricio Ávila, CBIH filed five patents in just five weeks and aims to file more than 15 patents by year-end. The company has also developed a Patent Application Filing Guide for the U.S. market, strengthening its position for potential strategic alliances with major pharmaceutical companies.
Cannabis Bioscience International Holdings (CBIH) ha ampliato significativamente il suo portafoglio di brevetti presentando sei domande di brevetto utility non provvisorie per terapie a base di cannabinoidi. I brevetti riguardano trattamenti per il cancro pancreatico, il cancro al seno, l'herpes zoster, la menopausa, l'osteoartrite del ginocchio e il COVID-19/Influenza. Sotto la guida del nuovo avvocato in tema di brevetti Mauricio Ávila, CBIH ha presentato cinque brevetti in sole cinque settimane e ha l'obiettivo di presentare più di 15 brevetti entro la fine dell'anno. L'azienda ha anche sviluppato una Guida alla Presentazione delle Domande di Brevetto per il mercato statunitense, rafforzando la sua posizione per potenziali alleanze strategiche con grandi aziende farmaceutiche.
Cannabis Bioscience International Holdings (CBIH) ha ampliado significativamente su cartera de patentes al presentar seis solicitudes de patentes no provisionales utility para terapias basadas en cannabinoides. Las patentes cubren tratamientos para el cáncer de páncreas, cáncer de mama, herpes zóster, menopausia, osteoartritis de rodilla y COVID-19/Influenza. Bajo la dirección del nuevo abogado de patentes Mauricio Ávila, CBIH presentó cinco patentes en solo cinco semanas y tiene como objetivo presentar más de 15 patentes para fin de año. La compañía también ha desarrollado una Guía de Presentación de Solicitudes de Patentes para el mercado estadounidense, fortaleciendo su posición para posibles alianzas estratégicas con grandes compañías farmacéuticas.
대마 생명 과학 국제 홀딩스(CBIH)는 카나비노이드 기반 요법에 대한 6개의 비유예 유틸리티 특허 출원을 통해 특허 포트폴리오를 크게 확대했습니다. 해당 특허는 췌장암, 유방암, 대상포진, 폐경, 무릎 골관절염 및 COVID-19/인플루엔자 치료를 포함합니다. 새로 임명된 특허 변호사 마우리시오 아빌라의 지휘 아래 CBIH는 단 5주 만에 5개의 특허를 제출했으며 연말까지 15개 이상의 특허를 제출할 계획입니다. 또한 이 회사는 미국 시장을 위한 특허 출원 가이드를 개발하여 주요 제약 회사와의 잠재적 전략적 제휴를 위한 입지를 강화했습니다.
Cannabis Bioscience International Holdings (CBIH) a considérablement élargi son portefeuille de brevets en déposant six demandes de brevets utility non provisoires pour des thérapies à base de cannabinoïdes. Les brevets couvrent des traitements contre le cancer du pancréas, le cancer du sein, le zona, la ménopause, l'arthrose du genou et le COVID-19/Grippe. Sous la direction du nouvel avocat en brevets Mauricio Ávila, CBIH a déposé cinq brevets en seulement cinq semaines et vise à en déposer plus de 15 d'ici la fin de l'année. L'entreprise a également élaboré un Guide de Dépôt de Brevets pour le marché américain, renforçant ainsi sa position pour des alliances stratégiques potentielles avec de grandes entreprises pharmaceutiques.
Cannabis Bioscience International Holdings (CBIH) hat sein Patentportfolio erheblich erweitert, indem es sechs nichtprovisorische Utility-Anmeldungen für cannabinoidbasierte Therapien eingereicht hat. Die Patente decken Behandlungen für Bauchspeicheldrüsenkrebs, Brustkrebs, Gürtelrose, Menopause, Kniearthrose und COVID-19/Influenza ab. Unter der Leitung des neu ernannten Patentanwalts Mauricio Ávila hat CBIH innerhalb von nur fünf Wochen fünf Patente eingereicht und strebt an, bis zum Jahresende mehr als 15 Patente anzumelden. Das Unternehmen hat auch einen Leitfaden zur Einreichung von Patentanmeldungen für den US-Markt entwickelt, um seine Position für potenzielle strategische Allianzen mit großen Pharmaunternehmen zu stärken.
- Filed six new utility non-provisional patent applications for various medical conditions
- Rapid patent filing pace - five patents in five weeks
- Strategic positioning for potential pharmaceutical industry partnerships
- Development of comprehensive U.S. Patent Application Filing Guide
- None.
Houston, Texas--(Newsfile Corp. - October 28, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) trading on the OTC Markets under the ticker symbol CBIH has reached a major milestone in expanding its patent portfolio, filing six utility non-provisional applications for cannabinoid-based therapies that address underserved medical conditions.
These patents cover therapeutic innovations for conditions such as pancreatic cancer (No. 18/905,128), breast cancer (No. 18/918,386), herpes zoster (No. 18/920,359), menopause (No. 18/921,140), knee osteoarthritis (No. 18/922,127), and COVID-19/Influenza (No. 18/924,087), with Neurocann's patent application set for submission this week. These filings highlight CBIH's dedication to addressing urgent healthcare needs and advancing alternative therapeutic solutions.
The innovations protected by these patents position CBIH as an attractive partner for strategic alliances with pharmaceutical and biotech firms, granting a meaningful and sustained advantage in the industry ecosystem. Thus, it facilitates access to additional resources for research, development, and broader distribution channels, enabling the company to capitalize on multiple revenue streams.
Following the appointment of Mr. Mauricio Ávila, Esq., a seasoned patent attorney with a dual background as a pharmaceutical chemist and legal expert, CBIH's intellectual property (IP) strategy has seen remarkable growth. With 15 years of experience in patent searching, drafting, prosecution, and litigation for leading multinational corporations across the pharmaceutical, biotechnology, cosmetics, and food sectors, Mr. Ávila has brought invaluable expertise to CBIH. His strategic leadership has enabled the company to file five patents in a record-breaking five-week period. Guided by his approach, CBIH is on a promising path to achieve its ambitious goal of perhaps filing more than 15 patents by year-end. This alignment of R&D and IP protection strengthens CBIH's innovations, creating a lasting competitive advantage.
"With a strengthened IP position, CBIH is poised to become an appealing alliance in a highly competitive landscape alongside pharmaceutical leaders in the likes of AbbVie, Sanofi U.S., Merck, Bristol Myers Squibb, Pfizer, and Roche, who are also advancing cannabinoid-based innovations," says Mr. John Jones, CBIH Treasurer and Director. "Under Mr. Ávila's guidance, we've come to realize that our medical department's advancements are exposed without comprehensive IP protection. As a result, we have taken decisive action to build a robust patent portfolio," he adds.
CBIH has also created a Patent Application Filing Guide tailored specifically for the U.S. market. This innovative resource consolidates previously fragmented information into a single, accessible document, offering comprehensive guidance and support for patent applicants navigating the U.S. filing process.
In summary, CBIH is committed to positioning cannabis as a first-line treatment for a wide range of medical conditions. Securing these intellectual property rights unlocks transformative research opportunities and establishes a new benchmark in patient care by employing cannabinoids as therapeutic agents.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227987
FAQ
What new patents has CBIH filed in 2024?
How many patents does CBIH plan to file by the end of 2024?
What is CBIH's new patent strategy under Mauricio Ávila?
